Jun 7, 2018
North America
From 2007 to 2016, the internalization of more new active substances (NASs) has allowed for extensive opportunity in the market. These changes have favored a smaller margin in approval times and a larger opportunity to extend them to patient populations globally....
Read More
Nov 20, 2017
Europe
After much anticipation and uncertainty, the European Medicines Agency (EMA) has a new home, post-Brexit. It’s Amsterdam! The Council of European Union comprised of 27 EU member states arrived at the decision on Monday, November 20 after three rounds of voting...
Read More
Aug 13, 2015
Europe
Over the last two decades, biologics have revolutionized the treatment of illnesses such as diabetes, cancer, rheumatoid arthritis and hepatitis. However, many prominent biologics are about to have their patents expire in the U.S., making way for biosimilars....
Read More